

# GOPEN ACCESS

**Citation:** Fu Y, Yin Y, Wu X, Li Y, Xiang A, Lu Y, et al. (2021) Clinical outcomes after small-incision lenticule extraction versus femtosecond laserassisted LASIK for high myopia: A meta-analysis. PLoS ONE 16(2): e0242059. https://doi.org/ 10.1371/journal.pone.0242059

**Editor:** Yu-Chi Liu, Singapore Eye Research Institute, SINGAPORE

Received: May 12, 2020

Accepted: October 27, 2020

Published: February 8, 2021

**Peer Review History:** PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: https://doi.org/10.1371/journal.pone.0242059

**Copyright:** © 2021 Fu et al. This is an open access article distributed under the terms of the <u>Creative</u> Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the manuscript and its <u>Supporting</u> information files.

RESEARCH ARTICLE

# Clinical outcomes after small-incision lenticule extraction versus femtosecond laser-assisted LASIK for high myopia: A meta-analysis

Yanyan Fu<sup>1,2,3</sup>, Yewei Yin<sup>1,2,3</sup>, Xiaoying Wu<sup>1,2,3</sup>, Yuanjun Li<sup>1,2,3</sup>, Aiqun Xiang<sup>1,2,3</sup>, Ying Lu<sup>1,2,3</sup>, Qiuman Fu<sup>1,2,3</sup>, Tu Hu<sup>1,2,3</sup>, Kaixuan Du<sup>1,2,3</sup>, Dan Wen<sup>1,2,3</sup>\*

Department of Ophthalmology, XiangYa Hospital, Central South University, Changsha, Hunan, China,
 Eye Center of Xiangya Hospital, Central South University, Changsha, Hunan, China,
 Hunan Key Laboratory of Ophthalmology, Changsha, Hunan, China

So These authors contributed equally to this work.

\* wendan@csu.edu.cn

# Abstract

# Aim

To compare postoperative clinical outcomes of high myopia after small-incision lenticule extraction (SMILE) and femtosecond laser-assisted laser in situ keratomileusis (FS-LASIK).

# Methods

From March 2018 to July 2020, PubMed, MEDLINE, Embase, the Cochrane Library, and several Chinese databases were comprehensively searched. The studies meeting the criteria were selected and included; the data were extracted by 2 independent authors. The clinical outcome parameters were analyzed with RevMan 5.3.

# Results

This meta-analysis included twelve studies involving 766 patients (1400 eyes: 748 receiving SMILE and 652 receiving FS-LASIK). Pooled results revealed no significant differences in the following outcomes: the logarithm of the mean angle of resolution (logMAR) of postoperative uncorrected distance visual acuity (weighted mean difference (WMD) = -0.01, 95% confidence interval (CI): -0.02 to 0.00,  $I^2 = 0\%$ , P = 0.07 at 1 mo; WMD = -0.00, 95% CI: -0.01 to 0.01,  $I^2 = 0\%$ , P = 0.83 at 3 mo; WMD = -0.00, 95% CI: -0.01 to 0.00,  $I^2 = 32\%$ , P = 0.33 in the long term), and the postoperative mean refractive spherical equivalent (WMD = -0.03, 95% CI: -0.09 to 0.03,  $I^2 = 13\%$ , P = 0.30). However, the SMILE group had significantly better postoperative corrected distance visual acuity (CDVA) than the FS-LASIK group (WMD = -0.04, 95% CI, -0.05 to -0.02,  $I^2 = 0\%$ , P<0.00001). In the long term, postoperative total higher-order aberration (WMD = -0.09, 95% CI: -0.10 to -0.07,  $I^2 = 7\%$ , P<0.00001) and postoperative spherical aberration (WMD = -0.15, 95% CI: -0.19 to -0.11,  $I^2 = 29\%$ , P<0.00001) were lower in the SMILE group than in the FS-LASIK group; a significant difference was also found in postoperative coma (WMD = -0.05, 95% CI: -0.06 to -0.03,  $I^2 = 30\%$ , P<0.00001). **Funding:** Science and Technology Project of Changsha Project name: Clinical study of small incision lenticule extraction in the treating myopia. Project number: Kq1701079 Changsha Health and Family Planning Commision is responsible for this project.

**Competing interests:** The authors have declared that no competing interests exist.

Abbreviations: CDVA, corrected distance visual acuity; FS, Femtosecond laser; FS-LASIK, Femtosecond laser assisted laser in situ keratomileusis; NOS, Newcastle-Ottawa scale; PRISM, Preferred reporting items for systematic reviews and meta-analyses; SE, Spherical equivalent; SMILE, Small incision lenticule extraction; tHOA, Total higher-order aberration; UDVA, Uncorrected distance visual acuity; WMD, Weighted mean difference.

#### Conclusion

For patients with high myopia, both SMILE and FS-LASIK are safe, efficacious and predictable. However, the SMILE group demonstrated advantages over the FS-LASIK group in terms of postoperative CDVA, while SMILE induced less aberration than FS-LASIK. It remains to be seen whether SMILE can provide better visual quality than FS-LASIK; further comparative studies focused on high myopia are necessary.

# Introduction

With the increasing prevalence of high myopia, high requirements have been placed on the predictability of refractive surgery and on the visual quality that it achieves [1]. Patients with high myopia face longer and more difficult postoperative wound healing than those with low to moderate myopia; this challenge increases the risk of stromal haze formation and refractive regression and reduces the long-term stability of the refractive correction [2,3]. In addition, high myopia means a high degree of correction during the procedures, and the thin remaining part of the cornea will be at risk for corneal ectasia [4]; thus, it is generally difficult to reach the expected degree of postoperative visual quality [5]. Owing to these conditions, the correction of high myopia carries many challenges for refractive surgeons; failure to use an appropriate correction strategy could lead to significant visual impairment and an elevated risk of sight-threatening complications [6,7]. Consequently, the relative merits of different types of corneal refractive surgery for high myopia are not only a concern for patients but also an important research topic for refractive surgeons.

Recently, small-incision lenticule extraction (SMILE) and femtosecond laser-assisted laser in situ keratomileusis (FS-LASIK) have become the most popular options in corneal refractive surgery. FS-LASIK has proven to be effective, safe and predictable for treating myopia [8]. However, the creation of the corneal flap and the ablation of the stroma limit the application of FS-LASIK, as this procedure may increase the risk of treatment regression, changes in corneal biomechanics, and flap complications. SMILE has emerged as a new option for patients; in this procedure, the production of a corneal flap is replaced by a minimized incision to reduce corneal-flap complications and dry eye [9].

Many scholars have focused on the clinical efficacy of these two types of refractive surgery. However, most studies comparing SMILE and FS-LASIK consider correction of low to moderate myopia [10–13] or analyze all included eyes without further grouping by degree of myopia [14]. Only a few comparative studies have targeted populations with high myopia. Hence, the aim of this meta-analysis is to review on the existing comparative studies in greater depth to understand the differences between SMILE and FS-LASIK in terms of safety, efficacy, predictability, and visual quality when used to correct high myopia.

## Material and methods

A meta-analysis was performed in accordance with the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines [15], following the generally accepted recommendations [16].

#### **Ethics statement**

This study followed the tenets of the Declaration of Helsinki and was approved by the ethics committee of XiangYa Hospital, Central South University. Informed written consent was obtained from all participants.

**Search strategy.** To gather as many records as possible on the comparison between SMILE and LASIK for treating high myopia, two reviewers independently searched the following electronic databases: PubMed, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL) and three Chinese databases (CNKI, WANFANG and Weip). The following keywords were used in the search: high myopia (e.g., high myopia, high short-sight, high near-sighted or high correction), LASIK (e.g., LASIK or keratomileusis, femtosecond laser in situ keratomileusis) and SMILE (e.g., SMILE, lenticule extraction, small-incision lenticule extraction). The search process for PubMed is shown in Fig 1 (Flow diagram of the literature search).


No date or language restrictions were applied to the electronic search. Our literature search work began in March 2018 and ended in July 2020. During this period, we searched once a month to observe whether there was any newly published literature meeting the inclusion criteria and consider whether to include it. At the end of the last search, we had identified 12 candidate articles. First, two reviewers independently screened the titles and abstracts; then, the potentially relevant reports were assessed to determine whether they were complete manuscripts; finally, the two researchers selected the articles in accordance with our inclusion criteria. Any disagreements between the reviewers were eliminated through discussion, and the two reviewers eventually reached a consensus about the results and interpretation.


**Inclusion criteria.** This meta-analysis adopted the following inclusion criteria for articles: (1) study design: randomized or nonrandomized clinical trials; (2) population: patients with high myopia (preoperative spherical equivalent (SE) refractive error -6.00 diopters or worse, or the simultaneous presence of spherical refractive error worse than -5.00 diopters and cylindrical refractive error worse than -1.00); (3) intervention: SMILE versus FS-LASIK; (4) outcome variables: visual acuity or aberration or other parameters that represent clinical outcomes; (5) data: original clinical articles with independent data; (6) no date restrictions on the included studies.

**Exclusion criteria.** The following classes of articles were excluded: 1) repeated publications; 2) unpublished literature; 3) abstracts, case reports, reviews, letters, comments, noncomparative studies and nonhuman investigations; and 4) reports with incorrect or incomplete data.

**Data extraction.** Two independent reviewers extracted data from the included studies using a customized form. In order to reduce the heterogeneity caused by variation in follow-up intervals, some outcomes are presented in subgroups defined by the follow-up time (e.g., 1 mo, 3 mo or in the long term after surgery). The following parameters were extracted:

- The primary outcome measures represented postoperative safety, efficacy and predictability, for instance, the logarithm of the mean angle of resolution (logMAR) values of uncorrected distance visual acuity (UDVA), the logMAR values of corrected distance visual acuity (CDVA), and postoperative mean refractive SE.
- 2. The secondary outcome measures were various objective parameters of aberration suggesting postoperative visual quality, including total higher-order aberration (tHOA), spherical aberration, and coma.
- 3. If there were multiple reports for a particular study, only the data from the most recent and representative publication were extracted.





https://doi.org/10.1371/journal.pone.0242059.g001

#### Quality assessment

Because it is difficult to achieve completely randomized, controlled, and double-blind experimental design in clinical studies of FS-LASIK and SMILE for myopia, only one study [20] was a randomized controlled trial; most of the included studies were nonrandomized comparative trials. The quality of the included studies was assessed with the Newcastle-Ottawa Scale (NOS), which was adopted to evaluate the cohorts. The scores of these 12 included studies are presented in Table 1, along with judgments about each risk-of-bias item for each included study

Study or subgroup	Year	Design	Language		SMILE group		FS-LASIK group	Follow-up	NOS
				Eyes (n)	Preop mean SE (D)	Eyes (n)	Preop mean SE (D)	(mo)	
Bingjie Wang [2]	2016	СТ	English	50	-7.60±1.12 (>-6.00)	56	-7.68±1.19 (>-6.00)	12 mo	6
Bingjie Wang [ <u>3</u> ]	2015	CT (prospective)	English	47	-7.46±1.11 (≥-6.00)		-7.44±1.13 (≥-6.00)	12 mo	7
Yishan Qian [6]	2020	CT (prospective)	English	51	Sum of the spherical and cylindrical refractive error (-10.00 ~14.00)		Sum of the spherical and cylindrical refractive error (-10.00 ~14.00)	6 mo	7
Tian Han [7]	2020	СТ	English	75	-8.79±1.83 (-6.00 ~12.25)	46	-9.17±2.03 (-6.25 ~12.25)	24 mo	6
Likun Xia [ <u>17</u> ]	2018	CT (prospective)	English	78	-8.11±1.09 (-6.00~-12.00)	65	-8.05±1.12 (-6.00~-12.00)	36 mo	7
Tian Han [ <u>18</u> ]	2018	СТ	English	60	-6.54±1.69 (≥−6.00)	41	-7.15±1.92 (≥−6.00)	36 mo	7
Congrong Jing [19]	2018	CT (prospective)	Chinese	134	-6.00~-10.00	106	-6.00~-10.00	3 mo	8
Guofu Chen [20]	2017	RCT	Chinese	64	-9.59±0.57 (>-9.00)	64	-9.77±0.56 (>-9.00)	6 mo	6
Xiaojing Li [21] 2015		CT	English	55	Spherical: -6.00±1.39	51	Spherical: -6.18±1.61	6 mo	6
					Cylindrical: -0.66±0.70		Cylindrical: -0.83±0.66		
					(≥−6.00)		(≥−6.00)		
Yueming Zhou [22]	2016	СТ	Chinese	66	-7.58±2.14 (-6.125 ~ -9.75)	66	-7.62±1.83 (-6.00~-9.875)	6 mo	6
Xueyi Zhou [23]	2019	СТ	English	39	-10.79±0.81 (-10.00~-13.00)	34	-11.06±0.99 (-10.00~-14.50)	24 mo	6
Iben Bach Pedersen [24]	2014	СТ	English	29	-6.00~-10.5	35	-6.00 to -10.5	12 mo	6

#### Table 1. Characteristics of the 10 included studies.

\*CT: nonrandomized comparative trial; CT (prospective): prospective, nonrandomized comparative trial; RCT: randomized controlled trial

\*Preop mean SE (D): preoperative mean refractive spherical equivalent in diopters; the value in parentheses indicates the range of spherical equivalent values.

https://doi.org/10.1371/journal.pone.0242059.t001

(Fig 2: Judgments about each risk-of-bias item for each included study). The average NOS score of these 12 studies was 6.5 on a scale from 0 (lowest quality) to 9 (highest quality).

#### Statistical analysis

Meta-analysis was conducted in the statistical program RevMan 5.3, using weighted mean difference (WMD) and the corresponding 95% confidence interval (CI) to calculate the continuous outcomes. First, we used I<sup>2</sup> to test the heterogeneity of the included literature, and fixed-effect modeling was carried out when there was no statistical heterogeneity among studies ( $P \ge 0.1$ ,  $I^2 < 50\%$ ). Conversely, random-effect modeling was used for analysis when the included literature bore significant evidence of statistical heterogeneity (P < 0.1,  $I^2 > 50\%$ ). The results are presented as Z values, each corresponding to a P value; P values less than 0.05 were taken to indicate significant differences.

#### Sensitivity analysis and publication bias

In order to evaluate the robustness of the statistical model, a sensitivity analysis was carried out by "leave-one-out" analysis, in which we removed each included study in turn and quantified the influence of the individual studies on the pooled estimates. The results showed that when the study by Li-kun Xia et al. was excluded [17], the  $I^2$  value of UDVA within the 1 mo and 3 mo subgroups reduced sharply, and the P value showed a stable significant difference.




Fig 2. Judgments about each risk-of-bias item for each included study.

https://doi.org/10.1371/journal.pone.0242059.g002

Publication bias was estimated by applying Egger's test [25] (P = 0.207 to 1.000) and Begg's test [26] (P = 0.246 to 1.000) to the 12 studies; these tests indicated no obvious publication bias.

# **Results**

#### Search results

Fig 1 (Flow diagram of the literature search) is a flowchart of the selection of publications in this study. Initially, a total of 150 potentially eligible publications were selected from the electronic databases. After 30 duplicate reports were eliminated, the remaining 120 papers underwent title and abstract screening. Seventy-three studies were excluded for the following

reasons: 22 studies did not have a control group and merely gave separate descriptions of SMILE and FS-LASIK; 17 studies' control groups were not SMILE or FS-LASIK; 34 studies used subjects who did not have high myopia. Ultimately, 12 studies [2,3,6,7,17–24] met our inclusion criteria and were included in this meta-analysis.

#### Study characteristics and quality

Table 1 summarizes the main characteristics and the quality assessments of these 12 included studies, which were published from 2014 to 2020. A total of 766 patients (1400 eyes) were evaluated, with 748 eyes in the SMILE group (53%) and 652 eyes in the FS-LASIK group (47%). This meta-analysis identified 1 randomized controlled trial (RCT), 4 prospective comparative studies and 7 nonrandomized comparative studies investigating the effects of SMILE and FS-LASIK in the correction of high myopia. These studies were assessed using the NOS (Table 1), and we also formed judgments about each risk-of-bias item for each included study (Fig 2). Overall, these included studies had good quality (average NOS score: 6.5). S1 Table summarizes the surgical procedures used in the 12 included studies. The laser processes involved in SMILE and FS-LASIK were all performed using the VisuMax femtosecond laser system (Carl Zeiss Meditec), and the cap and flap thicknesses used in the 12 articles are also mentioned in S1 Table.

#### **Primary outcomes**

**The logMAR values of postoperative UDVA.** Of the 12 included articles, 6 [6,7,17–20] reported the logMAR values of postoperative UDVA. We excluded the study by Likun Xia et al. [17] in the first and second subgroups because the overall results were highly sensitive to its outcome. An examination of the forest plot showed that, for high myopia, there was no significant UDVA difference between the SMILE group and the FS-LASIK group at the 1- or 3-month follow-up (WMD = -0.01; 95% CI:-0.02 to0.00;  $I^2 = 0\%$ ; P = 0.07, WMD = -0.00; 95% CI:-0.01 to 0.01;  $I^2 = 0\%$ ; P = 0.83). These 6 studies were followed up for a longer period of time, and the same results were obtained in the long term after surgery (WMD = -0.00; 95% CI: -0.01 to 0.00,  $I^2 = 32\%$ ; P = 0.33). The same was true of the combined results (WMD = -0.00, 95% CI, -0.01 to 0.00,  $I^2 = 0\%$ , P = 0.13; Fig 3A: Primary outcomes).

The logMAR values of postoperative CDVA. Five studies [6,7,18,19,21] reported the log-MAR values of postoperative CDVA in patients with high myopia. The forest plot indicated that the SMILE group had significantly better postoperative CDVA than the FS-LASIK group in the correction of high myopia (WMD = -0.04, 95% CI: -0.05 to -0.02, I<sup>2</sup> = 0%, P<0.00001; Fig 3B: Primary outcomes).

**Postoperative mean refractive SE.** Six studies [6,7,17-19,21] compared the postoperative mean refractive SE outcomes between the SMILE and FS-LASIK groups. The forest plot showed no significant difference in postoperative mean refractive SE between the SMILE group and FS-LASIK group (WMD = -0.03, 95% CI: -0.09 to 0.03, I<sup>2</sup> = 13%, P = 0.30; Fig 3C: **Primary outcomes**).

#### Secondary outcomes

**Aberration.** Four studies [17,18,20,21] presented data on postoperative aberration at long-term follow-ups. We extracted 3-year postoperative data from the studies by Likun Xia [17] and Tian Han [18], and we extracted 6-month postoperative data from the studies by Guofu Chen [20] and Xiaojing Li [21]. Due to measurement bias, there was heterogeneity among these 4 studies; Table 2 shows the differences in the measurement of aberrations in the 4 included studies.

		SMILE				LASIK			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Tota	I Me	an	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
1.1.1 1 mo										
Congrong Jing 2018	-0.01	0.05	13	4 -0.0	001	0.06	106	17.0%	-0.01 [-0.02, 0.01]	
Guofu Chen 2017	-0.03	0.04	6	4 -0	.02	0.06	64	11.0%	-0.01 [-0.03, 0.01]	and the second sec
Yishan Qian 2020	0.03	0.12	5	1 0	.05	0.11	45	1.6%	-0.02 [-0.07, 0.03]	
Subtotal (95% CI)			24	9			215	29.7%	-0.01 [-0.02, 0.00]	•
Heterogeneity: Chi² = Test for overall effect:				; I² = 0	%					
1.1.2 3 mo										
Congrong Jing 2018	-0.021	0.05	13	4 -0.0	025	0.06	106	17.0%	0.00 [-0.01, 0.02]	
Guofu Chen 2017	-0.03	0.04	6	4 -0	.03	0.06	64	11.0%	0.00 [-0.02, 0.02]	
Yishan Qian 2020 Subtotal (95% CI)	0.03	0.12	5 24		.05	0.11	45 215	1.6% 29.7%	-0.02 [-0.07, 0.03] 0.00 [-0.01, 0.01]	•
Heterogeneity: Chi² = Test for overall effect: .				; I² = 0	%					
1.1.3 Long Term										
Congrong Jing 2018	-0.021	0.05	13	4 -0.0	025	0.06	106	17.0%	0.00 [-0.01, 0.02]	
Guofu Chen 2017		0.04				0.06	64	11.0%	0.00 [-0.02, 0.02]	
Likun Xia 2018		0.04				0.06	65		-0.01 [-0.03, 0.01]	
Tian Han 2018		0.08				0.00	41			
Tian Han 2018 Tian Han 2020		0.08				0.09	41		-0.03 [-0.06, 0.00] -0.02 [-0.06, 0.02]	
							40			
Yishan Qian 2020	0.03	0.12			.08	0.14			-0.05 [-0.10, 0.00]	
Subtotal (95% CI)			46				367	40.7%	-0.00 [-0.01, 0.00]	
Heterogeneity: Chi² = Test for overall effect: .				;  *= 3	2%					
Total (95% CI) Heterogeneity: Chi <sup>2</sup> = Test for overall effect: Test for subaroup diffe	Z=1.49	(P = 0.	13)	17); I² =					-0.00 [-0.01, 0.00]	-0.1 -0.05 0 0.05 C Favours [SMILE] Favours [FS-LASIK]
Heterogeneity: Chi² = Test for overall effect: Test for subaroup diffi	Z=1.49	(P = 0. Chi² =	P = 0.4 13)	df = 2		0.36).		%	-0.00 [-0.01, 0.00] Difference	
Heterogeneity: Chi² = Test for overall effect: Test for subaroup diffe <b>}</b>	Z = 1.49 erences: SMI	(P = 0. Chi² =	P = 0.4 13) 2.07.	df = 2	(P = .ASIF	0.36). (		% Mean		Favours [SMILE] Favours [FS-LASIK]
Heterogeneity: Chi <sup>2</sup> = Test for overall effect: Test for subaroup diffe Study or Subgroup	Z = 1.49 erences: SMI	(P = 0. Chi <sup>2</sup> = LE <u>SD To</u>	P = 0.4 13) 2.07.	t7);  ² = df = 2 FS-L	(P = .ASIF SD	0.36). (	l² = 3.3	% Mean <u>ht IV, I</u>	Difference	Favours [SMILE] Favours [FS-LASIK] Mean Difference
Heterogeneity: Chi <sup>2</sup> = Test for overall effect: Test for subaroup diffe Study or Subgroup Likun Xia 2018	Z = 1.49 erences: SMI Mean	(P = 0. Chi <sup>2</sup> = LE <u>SD To</u> 18	P = 0.4 13) 2.07. <u>etal M</u> 78 -	df = 2 FS-L	(P = .ASI <u>SD</u> 0.19	0.36). ( <u>Total</u>	² = 3.3 Weig	% Mean ht IV.I % -0.01	Difference Fixed, 95% Cl	Favours [SMILE] Favours [FS-LASIK] Mean Difference
Heterogeneity: Chi <sup>2</sup> = Test for overall effect. Test for subgroup diff Study or Subgroup Likun Xia 2018 Tian Han 2018	Z = 1.49 erences: SMI <u>Mean</u> -0.07 0	(P = 0. Chi <sup>2</sup> = LE <u>SD To</u> 18 .07	P = 0.4 13) 2.07. <u>Mai M</u> 78 - 60 -	df = 2 <b>FS-L</b> 0.06	(P = . <b>ASI</b> <u>SD</u> 0.19 0.08	0.36). ( <u>Total</u> 65	I <sup>2</sup> = 3.3 <u>Weig</u> 5.8 23.8	% Mean <u>ht IV, I</u> % -0.01 % -0.03	Difference Fixed, 95% Cl	Favours [SMILE] Favours [FS-LASIK] Mean Difference
Heterogeneity: Chi <sup>2</sup> = Test for overall effect: Test for subaroup diffe Study or Subgroup Likun Xia 2018 Tian Han 2018 Tian Han 2020	Z = 1.49 erences: SMI <u>Mean</u> -0.07 0 -0.11 0	(P = 0. Chi <sup>2</sup> = <u>SD To</u> 18 07 07	P = 0.4 13) 2.07. <u>tal M</u> 78 - 60 - 75 -	l7); I <sup>2</sup> = df = 2 FS-L lean 0.06 ↓ 0.08 ↓	(P = <u>ASIP</u> <u>SD</u> 0.19 0.08 0.08	0.36). ( <u>Total</u> 65 41	I <sup>2</sup> = 3.3 <u>Weig</u> 5.8 23.8	Mean           ht         IV. I           %         -0.01           %         -0.03           %         -0.03	Difference Fixed, 95% Cl [0.07, 0.05] 8 [-0.06, 0.00]	Favours [SMILE] Favours [FS-LASIK] Mean Difference
Heterogeneity: Chi <sup>2</sup> = Test for overall effect: Test for subaroup diff Study or Subgroup Likun Xia 2018 Tian Han 2018 Tian Han 2020 Xueyi Zhou 2019	Z = 1.49 erences: <u>SMI</u> -0.07 0 -0.11 0 -0.11 0	(P = 0. Chi <sup>2</sup> = LE <u>SD To</u> 18 07 07 13	P = 0.4 13) 2.07. <u>tal M</u> 78 - 60 - 75 - 39	I7); I <sup>2</sup> = df = 2 FS-L lean 0.06 0.08	(P = .ASII <u>SD</u> 0.19 0.08 0.08 0.15	0.36). ( <u>Total</u> 65 41 46	<b>Weig</b> 5.8 23.8 27.7 5.2	Mean           ht         IV. I           %         -0.01           %         -0.03           %         -0.03           %         -0.02	Difference Fixed, 95% Cl [-0.07, 0.05] [-0.06, 0.00] [-0.06, -0.00]	Favours [SMILE] Favours [FS-LASIK] Mean Difference
Heterogeneity. Chi <sup>a</sup> = Test for overall effect. Test for subaroup diffi Study or Subaroup Likun Xia 2018 Tian Han 2018 Tian Han 2020 Xueyi Zhou 2019 Yishan Qian 2020 Total (95% CI)	Z = 1.49 erences: <u>Mean</u> -0.07 0 -0.11 0 -0.11 0 0 0 -0.07 0	(P = 0. Chi <sup>2</sup> = <u>SD To</u> 18 07 13 06 3	P = 0.4 13) 2.07. tal <u>M</u> 78 - 60 - 75 - 39 51 -	FS-L I = 2 FS-L Iean 0.06 0.08 0.08 0.02 0.02 0.02 0.02	(P = .ASII <u>SD</u> 0.19 0.08 0.08 0.15	0.36). ( <u>Total</u> 65 41 46 34 45	I <sup>≇</sup> = 3.3 <u>Weig</u> 5.8 23.8 27.7 5.2 37.6	Mean           Int         IV, I           %         -0.01           %         -0.03           %         -0.03           %         -0.03           %         -0.03           %         -0.03           %         -0.05	Difference ixed, 95% Cl [-0.07, 0.05] ]-0.06, 0.00] [-0.06, -0.00] [-0.06, 0.00]	Favours [SMILE] Favours [FS-LASIK]
Heterogeneity. Chi <sup>a</sup> = Test for overall effect. Test for subaroup diffi S Study or Subaroup Likun Xia 2018 Tian Han 2018 Tian Han 2018 Tian Han 2018 Tian Han 2018 Yishan Qian 2020 Total (95% CI) Heterogeneity: Chi <sup>a</sup> = 2	Z = 1.49 erences: -0.07 0 -0.11 0 -0.11 0 0 0 -0.07 0	(P = 0. Chi <sup>2</sup> = <u>SD To</u> 18 07 13 06 3 4 (P = 0	P = 0.4 13) 2.07. <b>ttal M</b> 78 - 60 - 75 - 39 51 - <b>51</b> - <b>603</b> 1.63); P	FS-L I = 2 FS-L Iean 0.06 0.08 0.08 0.02 0.02 0.02 0.02	(P = .ASII <u>SD</u> 0.19 0.08 0.08 0.15	0.36). ( <u>Total</u> 65 41 46 34 45	I <sup>≇</sup> = 3.3 <u>Weig</u> 5.8 23.8 27.7 5.2 37.6	Mean           Int         IV, I           %         -0.01           %         -0.03           %         -0.03           %         -0.03           %         -0.03           %         -0.03           %         -0.05	Difference Tixed, 95% CI [+0.07, 0.05] 2-0.06, 0.00] [+0.08, 0.04] [+0.08, 0.04]	Favours [SMILE] Favours [FS-LASIK] Mean Difference
Heterogeneity: Chi <sup>2</sup> = Test for overall effect. Test for subaroup diffi Study or Subaroup Likun Xia 2018 Tian Han 2020 Tian Han 2020 Yishan Qian 2020 Total (95% CI) Heterogeneity: Chi <sup>2</sup> = 2 Test for overall effect. Z	Z = 1.49 erences: -0.07 0 -0.11 0 -0.11 0 0 0 -0.07 0	(P = 0. Chi <sup>2</sup> = <u>SD To</u> 18 07 13 06 3 4 (P = 0	P = 0.4 13) 2.07. <b>ttal M</b> 78 - 60 - 75 - 39 51 - <b>51</b> - <b>603</b> 1.63); P	FS-L I = 2 FS-L Iean 0.06 0.08 0.08 0.02 0.02 0.02 0.02	(P = .ASII <u>SD</u> 0.19 0.08 0.08 0.15	0.36). ( <u>Total</u> 65 41 46 34 45	I <sup>≇</sup> = 3.3 <u>Weig</u> 5.8 23.8 27.7 5.2 37.6	Mean           Int         IV, I           %         -0.01           %         -0.03           %         -0.03           %         -0.03           %         -0.03           %         -0.03           %         -0.05	Difference Tixed, 95% CI [+0.07, 0.05] 2-0.06, 0.00] [+0.08, 0.04] [+0.08, 0.04]	Favours [SMILE] Favours [FS-LASIK]
Heterogeneity: Chi <sup>2</sup> = Test for overall effect. Test for subaroup diffi Study or Subaroup Likun Xia 2018 Tian Han 2020 Tian Han 2020 Yishan Qian 2020 Total (95% CI) Heterogeneity: Chi <sup>2</sup> = 2 Test for overall effect. Z	Z = 1.49 erences: <u>SMM</u> -0.07 0 -0.11 0 -0.11 0 0 0 -0.07 0 .56, df = 4 = 4.76 (F	(P = 0. Chi <sup>2</sup> = <u>SD To</u> 18 07 13 06 3 4 (P = 0	P = 0.4 13) 2.07. <b>ttal M</b> 78 - 60 - 75 - 39 51 - <b>51</b> - <b>603</b> 1.63); P	FS-L FS-L lean 0.06 0.08 0.02 1 0.02 1 2 2 0%	(P = <u>SD</u> 0.19 0.08 0.15 0.06 LAS	0.36). ( <u>Total</u> 65 41 46 34 45 231	Weig           58           23.8           27.7           5.2           37.6           100.0	Mean           ht         IV.1           %         -0.01           %         -0.03           %         -0.03           %         -0.05           %         -0.04	Difference Tixed, 95% CI [+0.07, 0.05] 2-0.06, 0.00] [+0.08, 0.04] [+0.08, 0.04]	Favours [SMILE] Favours [FS-LASIK]
Heterogeneity: Chi <sup>a</sup> = Test for overall effect: Test for subaroup diffu Study or Subgroup Likun Xia 2018 Tian Han 2018 Tian Han 2018 Tian Han 2020 Yishan Qian 2020 Total (95% CI) Heterogeneity: Chi <sup>a</sup> = 2 Test for overall effect: Z	Z = 1.49 erences: <u>SMM</u> -0.07 0 -0.11 0 -0.11 0 0 0 -0.07 0 .56, df = 4 = 4.76 (F	(P = 0. Chi <sup>2</sup> = <u>SD To</u> 18 07 13 06 3 (P = 0 × 0.00 IILE	P = 0.4 13) 2.07. <b>ttal M</b> 78 - 60 - 75 - 39 51 - <b>51</b> - <b>603</b> 1.63); P	FS-L FS-L lean 0.06 0.08 0.08 0.02 1 0.02 FS- FS- Comparison FS- Comparison	(P = <u>SD</u> 0.19 0.08 0.15 0.06 LAS	0.36). ( <u>Total</u> 65 41 46 34 45 <b>231</b>	Weig           58           23.8           27.7           5.2           37.6           100.0	Mean           ht         N.I.           %         -0.01           %         -0.03           %         -0.03           %         -0.05           %         -0.04	Difference (ixed, 95% Cl (-0.07, 0.05) 3 (-0.06, 0.00) (-0.06, 0.00) (-0.07, -0.03) [-0.05, -0.02]	Favours [SMILE] Favours [FS-LASIK]
Heterogeneity: Chi <sup>2</sup> = Test for overall effect: Test for subaroup diff Study or Subgroup Likun Xia 2018 Tian Han 2018 Tian Han 2020 Xueyi Zhou 2019 Yishan Qian 2020 Total (95% CI) Heterogeneity: Chi <sup>2</sup> = 2 Test for overall effect: Z	Z = 1.49 erences: <u>SMI</u> -0.07 0 -0.11 0 0 0 -0.11 0 0 0 -0.07 0 2.56, df = 4 Z = 4.76 (F	(P = 0. Chi <sup>2</sup> = LE SD To SD To 13 07 13 06 3 4 (P = 0 × < 0.00 IIILE SD T	P = 0.4 13) 2.07. <b>tal M</b> 778 - 60 - 75 - 51 - <b>51</b> - <b>103</b> 1.63); P 1001) <b>1001</b>	FS-L FS-L lean 0.06 0.08 0.08 0.02 1 0.02 FS- FS- Comparison FS- Comparison	(P = <u>ASIP</u> <u>SD</u> 0.19 0.08 0.08 0.08 0.06 <u>SE</u>	0.36). ( <u>Total</u> 65 41 46 34 45 231 <b>231</b> IK <u>) Tota</u>	Weig           5.8           23.8           27.7           5.2           37.6           100.0	Mean           ht         N.I           %         -0.01           %         -0.02           %         -0.03           %         -0.05           %         -0.04           Mean         Mean	Difference ixed, 95% Cl [-0.07, 0.05] i (-0.08, -0.00] i (-0.08, -0.04] [-0.08, -0.04] [-0.05, -0.02] 1 Difference	Favours [SMILE] Favours [FS-LASIK]
Heterogeneity: Chi <sup>2</sup> = Test for overall effect: Test for subaroup diffi Study or Subaroup Likun Xia 2018 Tian Han 2020 Tian Han 2020 Total (95% CI) Heterogeneity: Chi <sup>2</sup> = 2 Test for overall effect: Z Study or Subgroup Congrong Jing 2018	Z = 1.49 erences: <b>SMM</b> -0.07 -0.11 0 -0.11 0 -0.07 0 2.56, df = 4 Z = 4.76 (F SM Mean	(P = 0. Chi <sup>≠</sup> = <u>SD To</u> 18 07 13 06 3 4 (P = 0 0.00 <b>NILE</b> <u>SD 1</u> 0.39	P = 0.4 13) 2.07. <b>tal M</b> 	f7);  ₽ = fS-L eean 0.06    0.08    0.02    0.02    0.02    1 = 0% FS- Mean	(P = <u>ASIP</u> <u>SD</u> 0.19 0.08	0.36). ( <u>Total</u> 65 41 46 34 45 231 <b>231</b> <b>IK</b> <u>) Tota</u> 1 10	Weig           5.8           23.8           27.7           5.2           37.6           100.0           Il           Weig           5.8           23.8           27.7           5.2           37.6           100.0	Mean           ht         N, I           %         -0.01           %         -0.03           %         -0.03           %         -0.03           %         -0.03           %         -0.04           Mear           nth         IV.           %         -0.04           Mear           nth         IV.           %         -0.03	Difference Tixed, 95% Cl [-0.07, 0.05] 3-0.06, 0.00] [-0.06, 0.00] [-0.07, -0.03] [-0.05, -0.02] Difference Fixed, 95% Cl	Favours [SMILE] Favours [FS-LASIK]
Heterogeneity: Chi <sup>™</sup> = Test for overall effect: Test for subaroup diffu Study or Subaroup Likun Xia 2018 Tian Han 2020 Tian Han 2020 Yishan Qian 2020 Total (95% CI) Heterogeneity: Chi <sup>™</sup> = 2 Test for overall effect: Z Study or Subaroup Congrong Jing 2018 Likun Xia 2018	Z = 1.49 erences: <b>SMI</b> -0.07 0 -0.11 0 -0.11 0 0 0 -0.07 0 2.56, df = 4 (= 4.76 (F <b>SN</b> <u>Mean</u> -0.05	(P = 0. Chi <sup>≠</sup> = LE SD To SD To 13 07 07 13 06 3 4 (P = 0 0.00 NLE SD 1 0.39 0.34	P = 0.4 13) 2.07. 13) 2.07. 13) 14 14 13 134 78	T7); I <sup>2</sup> =       df = 2       FS-L       lean       0.06       0.08       0.08       0.02       1       = 0%       FS-L       Mean       0	(P = <u>SD</u> 0.19 0.08	0.36). ( <u>Total</u> 65 41 46 34 45 231 <b>IK</b> <u>1</u> 105 6	Weig           5.8           23.8           27.7           5.2           37.6           100.0           I           Weig           6           39.8           5           44.	Mean           ht         V. I           %         -0.03           %         -0.03           %         -0.03           %         -0.05           %         -0.04           Mear         -0.04           Mear         -0.04           Mear         -0.04           Mear         -0.04           0.04         -0.04	Difference (xed, 95% Cl (-0.07, 0.05) (-0.06, 0.00) (-0.06, -0.00) (-0.07, -0.03) (-0.05, -0.02) (-0.05, -0.02) Difference Fixed, 95% Cl 5 (-0.14, 0.04)	Favours [SMILE] Favours [FS-LASIK]
Heterogeneity: Chi <sup>2</sup> = Test for overall effect: Test for subaroup diff Study or Subaroup Likun Xia 2018 Tian Han 2018 Tian Han 2020 Yishan Qian 2020 Total (95% CI) Heterogeneity: Chi <sup>2</sup> = 2 Test for overall effect Z Study or Subaroup Congrong Jing 2018 Likun Xia 2018	Z = 1.49 erences: SMI Mean -0.07 0 -0.11 0 -0.11 0 0 0 0 -0.07 0 .56, df = 4 Z = 4.76 (F SM Mean -0.05	(P = 0. Chi <sup>2</sup> = LE <u>SD To</u> 07 13 06 3 4 (P = 0 * < 0.00 * < 0.00 * 0.39 0.34 0.34	P = 0.4 13) 2.07. tal M 778 - 60 - 75 - 51 - 51 - 603;  P 0001) 0001) 0001) 0001) 0001 00000 0001 00000	FS-L ean 0.06 0.08 0.02 0.02 1 -0.28 FS-L ean 0.02 -0.28 -0.28 -0.28	(P = <u>ASIP</u> <u>50</u> 0.19 0.08 0.08 0.15 0.06 0.06 0.31 0.16 0.88	0.36). ( <u>Total</u> 65 41 46 34 45 <b>231</b> <b>IK</b> <b>D</b> Total 1 100 5 6 5 4 3 4	Weig           5.8           23.8           27.7           5.2           37.6           100.0           al           Weig           5.8           5.7           5.2           37.6           100.0	Mean           ht         IV. I           %         -0.01           %         -0.03           %         -0.03           %         -0.02           %         -0.03           %         -0.04           Mean         -0.04           Mean         -0.04           44         -0.07           7%         -0.10	Difference ixed, 95% Cl [-0.07, 0.05] 3-0.08, 0.00] [-0.08, 0.04] [-0.07, -0.03] [-0.05, -0.02] 1Difference Fixed, 95% Cl 5 [-0.14, 0.04] 6 [-0.14, 0.02]	Favours [SMILE] Favours [FS-LASIK]
Heterogeneity: Chi <sup>2</sup> = Test for overall effect: Test for subaroup diff Study or Subgroup Likun Xia 2018 Tian Han 2018 Tian Han 2020 Xueyi Zhou 2019 Yishan Qian 2020 Total (95% CI) Heterogeneity: Chi <sup>2</sup> = 2 Test for overall effect Z Study or Subgroup Congrong Jing 2018 Tian Han 2018 Tian Han 2018 Tian Han 2020 Xiaojing Li 2015	Z = 1.49 erences: <b>SMI</b> -0.07 0 -0.07 0 -0.11 0 0 0 -0.07 0 .56, df = 4 Z = 4.76 (F <b>SN</b> Mean -0.05 -0.01 -0.14	(P = 0. Chi <sup>2</sup> = LE <u>SD To</u> 07 13 06 3 4 (P = 0 * < 0.00 * < 0.00 * 0.39 0.34 0.34	P = 0.4 13) 2.07. tal M 78 - 675 - 75 - 739 51 - 103 103 134 78 60 75 55	FS-L ean 0.06 0.08 0.02 0.02 0.02 = 0% FS- Mean 0 0.02 -0.28	(P = <u>ASIP</u> <u>50</u> 0.19 0.08 0.08 0.15 0.06 0.06 0.31 0.16 0.88 0.66	0.36). ( <u>Total</u> 65 41 46 34 45 <b>231</b> 1 10 5 6 5 4 1 10 5 6 3 4 3 5	Weig         58           23.8         27.7           5.2         37.6           100.0         37.6           4         Weig           5         44.1           5         5.4           1         5.5           1         4.1	Mean           ht         N, I           %         -0.01           %         -0.03           %         -0.03           %         -0.05           %         -0.05           %         -0.04           Mean         N////           nth         IV//           7%         -0.04           %         -0.07           %         0.0           %         -0.03           %         -0.04	Difference Tixed, 95% Cl [-0.07, 0.05] 3-0.06, 0.00] 2-0.08, 0.04] [-0.07, -0.03] - [-0.05, -0.02] - Difference Fixed, 95% Cl 5-0.14, 0.04] 6-0.04, 0.02] 4-0.09, 0.37] 9-0.25, 0.26]	Favours [SMILE] Favours [FS-LASIK]
Heterogeneity: Chi <sup>2</sup> = Test for overall effect. Test for subaroup diff Study or Subgroup Likun Xia 2018 Tian Han 2018 Tian Han 2020 Xueyi Zhou 2019 Yishan Qian 2020 Total (95% CI) Heterogeneity: Chi <sup>2</sup> = 2 Test for overall effect. Z Study or Subgroup Congrong Jing 2018 Likun Xia 2018 Tian Han 2018 Tian Han 2020 Xiaojing Li 2015 Yishan Qian 2020	Z = 1.49 erences: <b>SMII</b> -0.07 0 -0.07 0 -0.11 0 0 0 -0.07 0 2.56, df = 4 C 4.76 (F <b>Mean</b> -0.05 -0.01 -0.14 -0.45 -0.01 -0.14 -0.45	(P = 0. Chi <sup>≠</sup> = <u>SD To</u> <u>SD To</u> 18 07 13 06 3 3 4 (P = 0 × < 0.00 112 0.39 0.34 0.49 0.38 0.07	P = 0.4 13) 2.07. tal M 78 - 60 - 75 - 39 51 - 103 163); P 1001) Total 1 134 60 75 55 51	FS-L ean 0.06 i 0.08 i 0.02 i 0.03 i 0.05 i 0.	(P = <u>ASIP</u> <u>50</u> 0.19 0.08 0.08 0.15 0.06 0.06 0.31 0.16 0.88 0.66	0.36). ( Total 65 41 46 34 45 231 I 100 5 6 5 4 3 4 5 5 6 5 4 3 4 5 5 6 5 4 1 1 1 1 1 1 1 1 1 1 1 1 1	Weig           5.8           23.8           27.7           5.2           37.6           100.0           1           5           44.           5           4.1           5           4.1           5           4.1           5           2.2	Mean           tt         tt/line           0.010         -0.010           % -0.030         -0.030           % -0.030         -0.030           % -0.05         -0.04           mean         -0.04           Mean         -0.04           % -0.05         -0.04           % -0.05         -0.04           % -0.05         -0.06	Difference ixed, 95% Cl [-0.07, 0.05] 2-0.08, 0.00] [-0.06, -0.00] 2-0.08, 0.04] [-0.07, -0.03] - - - - - - - - - - - - -	Favours [SMILE] Favours [FS-LASIK]
Heterogeneity: Chi <sup>2</sup> = Test for overall effect: Test for subaroup diff Study or Subaroup Likun Xia 2018 Tian Han 2018 Tian Han 2020 Xueyi Zhou 2019 Yishan Gian 2020 Total (95% CI) Heterogeneity: Chi <sup>2</sup> = 2 Test for overall effect Z Study or Subaroup Congrong Jing 2018 Likun Xia 2018 Tian Han 2018 Tian Han 2018 Tian Han 2018 Yishan Gian 2020 Yishan Gian 2020 Total (95% CI)	Z = 1.49 Mean -0.07 0 -0.11 0 -0.11 0 -0.07 0 -0.07 0 -0.07 0 -0.06 -0.06 -0.06 -0.01 -0.14 -0.14 -0.25 0.1	(P = 0. Chi <sup>≈</sup> = ILE ISD To 07 07 13 06 3 4 (P = 0 × < 0.00 13 4 (P = 0 × < 0.00 13 0.34 0.39 0.34 0.49 0.86 0.7 0.8	P = 0.4 13) 2.07. <b>ital M</b> 2.07. <b>ital M</b> 2.07. <b>ital M</b> 50 - 51 - <b>ital M</b> 51 - <b>ital M</b> 75 - 51 134 75 55 51 <b>453</b>	FS-L lean 0.06   0.08   0.02   0.02   0.02   0.02   1.02   0.02   2 = 0% FS- Mean 0.05 -0.28 -0.24 -0.25 -0.15	(P = <u>SD</u> 0.19 0.08 0.08 0.15 0.06 0.06 0.31 0.16 0.66 0.93	0.36). ( Total 65 41 46 34 45 231 I 100 5 6 5 4 3 4 5 5 6 5 4 3 4 5 5 6 5 4 1 1 1 1 1 1 1 1 1 1 1 1 1	Weig           5.8           23.8           27.7           5.2           37.6           100.0           1           5           44.           5           4.1           5           4.1           5           4.1           5           2.2	Mean           tt         tt/line           0.010         -0.010           % -0.030         -0.030           % -0.030         -0.030           % -0.05         -0.04           mean         -0.04           Mean         -0.04           % -0.05         -0.04           % -0.05         -0.04           % -0.05         -0.06	Difference ixed, 95% Cl [-0.07, 0.05] 2-0.08, 0.00] [-0.07, -0.03] 	Favours [SMILE] Favours [FS-LASIK]
Heterogeneity. Chi <sup>™</sup> = Test for overall effect. Test for subaroup diffi Study or Subaroup Likun Xia 2018 Tian Han 2020 Tian Han 2020 Total (95% CI) Heterogeneity. Chi <sup>™</sup> = 2 Test for overall effect. Z Study or Subgroup Congrong Jing 2018 Likun Xia 2018 Tian Han 2020 Xiaojing Li 2015 Yishan Qian 2020 Total (95% CI)	Z = 1.49 Mean -0.07 0 -0.11	(P = 0, Chi <sup>™</sup> = <b>LE</b> <b>SD</b> To SD To SD To (07) 07 07 13 07 07 07 07 07 07 07 07 07 07 07 07 07	P = 0.4 13) 2.07. <b>tal M</b> 78 - 60 - 75 - 51 - <b>103</b>       	FS-L lean 0.06   0.08   0.02   0.02   0.02   0.02   1.02   0.02   2 = 0% FS- Mean 0.05 -0.28 -0.24 -0.25 -0.15	(P = <u>SD</u> 0.19 0.08 0.08 0.15 0.06 0.06 0.31 0.16 0.66 0.93	0.36). ( Total 65 41 46 34 45 231 I 100 5 6 5 4 3 4 5 5 6 5 4 3 4 5 5 6 5 4 1 1 1 1 1 1 1 1 1 1 1 1 1	Weig           5.8           23.8           27.7           5.2           37.6           100.0           1           5           44.           5           4.1           5           4.1           5           4.1           5           2.2	Mean           tt         tt/line           0.010         -0.010           % -0.030         -0.030           % -0.030         -0.030           % -0.05         -0.04           mean         -0.04           Mean         -0.04           % -0.05         -0.04           % -0.05         -0.04           % -0.05         -0.06	Difference ixed, 95% Cl [-0.07, 0.05] 2-0.08, 0.00] [-0.07, -0.03] 	Favours [SMILE] Favours [FS-LASIK]
Heterogeneity: Chi² = Test for overall effect: Test for subaroup diffe <b>3</b>	Z = 1.49 Mean -0.07 0 -0.11	(P = 0, Chi <sup>™</sup> = <b>LE</b> <b>SD</b> To SD To SD To (07) 07 07 13 07 07 07 07 07 07 07 07 07 07 07 07 07	P = 0.4 13) 2.07. <b>tal M</b> 78 - 60 - 75 - 51 - <b>103</b>       	FS-L lean 0.06   0.08   0.02   0.02   0.02   0.02   1.02   0.02   2 = 0% FS- Mean 0.05 -0.28 -0.24 -0.25 -0.15	(P = <u>SD</u> 0.19 0.08 0.08 0.15 0.06 0.06 0.31 0.16 0.66 0.93	0.36). ( Total 65 41 46 34 45 231 I 100 5 6 5 4 3 4 5 5 6 5 4 3 4 5 5 6 5 4 1 1 1 1 1 1 1 1 1 1 1 1 1	Weig           5.8           23.8           27.7           5.2           37.6           100.0           1           5           44.           5           4.1           5           4.1           5           4.1           5           2.2	Mean           tt         tt/limit           0.010         -0.010           % -0.03         -0.03           % -0.03         -0.03           % -0.05         -0.04           mean         -0.04           % -0.05         -0.04           % -0.05         -0.04           % -0.05         -0.04           % -0.05         -0.06	Difference ixed, 95% Cl [-0.07, 0.05] 2-0.08, 0.00] [-0.07, -0.03] 	Favours [SMILE] Favours [FS-LASIK]

3B: Forest plot showing the weighted mean difference of CDVA (logMAR) after SMILE versus FS-LASIK 3C: Forest plot showing the weighted mean difference of postoperative mean refractive SE after SMILE versus

FS-LASIK

SD = standard deviation; CI = confidence interval; df = degree(s) of freedom; I<sup>2</sup> = heterogeneity; Z = overall effect

Fig 3. Primary outcomes (A-C).

https://doi.org/10.1371/journal.pone.0242059.g003

Postoperative tHOA. The tHOA forest plots indicated significant differences between the two groups. For high myopia, the tHOA was increased in both the SMILE group and the FS-LASIK group, but the postoperative tHOA in the SMILE group was significantly lower than that in the FS-LASIK group as of long-term follow-up (WMD = -0.09, 95% CI:-0.10 to -0.07,  $I^2 = 7\%$ , P<0.00001; Fig 4A: Secondary outcomes).

Postoperative spherical aberration. SMILE also introduced less spherical aberration than FS-LASIK as of long-term follow-up (MD = -0.15, 95% CI: -0.19 to -0.11,  $I^2 = 29\%$ , P<0.00001; Fig 4B: Secondary outcomes).

Included studies	Types of refractive surgery	Different measurements of aberrations
Likun Xia et al [17]	SMILE VS Wavefront-guided FS-LASIK	HOAs, WASCA wavefront analyzer; Carl Zeiss Meditec AG, Jena, Germany
Tian Han et al [ <u>18]</u>	SMILE VS FS-LASIK	Pentacam HR, Type 70900, Wetzlar, Germany
Guofu Chen et al [20]	SMILE VS FS-LASIK	Pentacam; Oculus GmbH, Wetzlar, Germany
Xiaojing Li et al [21]	SMILE VS FS-LASIK	Pentacam; Oculus GmbH, Wetzlar, Germany

Table 2. Measurement bias of 3 included studies.

https://doi.org/10.1371/journal.pone.0242059.t002

**Postoperative coma.** For high myopia, no significant difference in postoperative coma was found between the SMILE group and the FS-LASIK group with long-term postoperative observation (WMD = -0.05, 95% CI: -0.06 to -0.03,  $I^2$  = 30%, P<0.00001; Fig 4C: Secondary outcomes).

#### Α

		SMILE		FA	LASIK			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight		IV, Fixed, 95% Cl
Guofu Chen 2017	0.28	0.07	66	0.36	0.06	66	70.4%	-0.08 [-0.10, -0.06]	
Likun Xia 2018	0.33	0.1	78	0.42	0.13	65	23.4%	-0.09 [-0.13, -0.05]	
Tian Han 2018	0.98	0.41	60	1.04	0.36	41	1.5%	-0.06 [-0.21, 0.09]	
Xiaojing Li 2015	0.952	0.23	55	1.111	0.22	51	4.7%	-0.16 [-0.24, -0.07]	
Total (95% CI)			259			223	100.0%	-0.09 [-0.10, -0.07]	•
Heterogeneity: Chi <sup>2</sup> :	= 3.22, d	f= 3 (P	= 0.36	i); I <sup>2</sup> = 79	6				
Test for overall effec									-0.2 -0.1 0 0.1 0.2 Favours (SMILE) Favours (FS-LASIK)
3									
		SMILE		FS	-LASIK			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean		Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Likun Xia 2018	0.26	0.31	78	0.35	0.19	65	23.9%	-0.09 [-0.17, -0.01]	
Tian Han 2018	0.41	0.16	60	0.59	0.18	41	35.1%	-0.18 [-0.25, -0.11]	
Xiaojing Li 2015	0.483	0.133	55	0.641	0.192	51	40.9%	-0.16 [-0.22, -0.09]	
Total (95% CI)			193			157	100.0%	-0.15 [-0.19, -0.11]	•
Heterogeneity: Chi <sup>2</sup> =	2.81, df	= 2 (P =	0.24);	<sup>2</sup> = 29%					-0.2 -0.1 0 0.1 0.2
Test for overall effect	Z=7.23	(P < 0.	00001)						Favours [SMILE] Favours [FS-LASIK]
3									
	5	SMILE		FS	LASIK			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% Cl
Guofu Chen 2017	0.24	0.06	66	0.29	0.05	66	90.0%	-0.05 [-0.07, -0.03]	
Tian Han 2018	0.21	0.17	60	0.21	0.14	41	8.7%	0.00 [-0.06, 0.06]	
Xiaojing Li 2015	-0.609	0.391	55	-0.507	0.431	51	1.3%	-0.10 [-0.26, 0.06]	
Total (95% CI)			181			158	100.0%	-0.05 [-0.06, -0.03]	•
Heterogeneity: Chi <sup>2</sup> =				<b>≈</b> = 30%					-0.5 -0.25 0 0.25 0.
		(P < 0.0)							

✓ 4A: Forest plot showing the weighted mean difference of tHOA after SMILE versus FS-LASIK

✓ 4B: Forest plot showing the weighted mean difference of spherical aberration after SMILE versus FS-LASIK

✓ 4C: Forest plot showing the weighted mean difference of coma after SMILE versus FS-LASIK

SD = standard deviation; CI = confidence interval; df = degree(s) of freedom;  $I^2$  = extent of heterogeneity; Z = overall effect

#### Fig 4. Secondary outcomes (A-C).

https://doi.org/10.1371/journal.pone.0242059.g004

## Discussion

This meta-analysis focused on patients with high myopia from the perspectives of postoperative safety, efficacy, predictability and visual quality after SMILE or FS-LASIK and performed a systematic comparative analysis.

During our screening of included studies, we found that published comparative studies of high myopia accounted for only a small proportion of studies comparing SMILE and FS-LA-SIK (17/104 = 16%). Among these comparative studies, RCTs were rare. It is generally recognized that the results of RCTs are more reliable than those of other experimental designs; we also found that the results of the RCT was always consistent with the combined results, and a similar phenomenon was found in other meta-analyses [27,28]. Thus, it is feasible and important to summarize and compare all published data because doing so can provide refractive surgeons with improved surgical treatment strategies for patients with high myopia. Although there was only 1 RCT out of our 12 included studies, most of the included studies reported long-term follow-up outcomes: 11 studies covered at least 2 years, and 3 studies covered 3 years (Table 1). In this meta-analysis, UDVA data were divided into subgroups according to the follow-up time (1 mo, 3 mo, or long term), and data on the other outcomes were extracted for long-term follow-up. In addition, no systematic comparison of such outcomes for high myopia has been published to date, which makes this meta-analysis meaningful.

The pooled results revealed that the SMILE group was not significantly different from the FS-LASIK group in the logMAR values of postoperative UDVA. In terms of efficacy, both SMILE and FS-LASIK brought good visual acuity in patients with high myopia; UDVA was significantly improved after operation. Sensitivity analysis revealed that Likun Xia's study had an outsized statistical influence on the analysis for the logMAR UDVA in the 1 mo subgroup and 3 mo subgroup; therefore, we excluded that study from these subgroups. After Likun Xia's study was excluded, there was no evidence of heterogeneity among the 3 remaining studies; therefore, a fixed-effect model was used in this analysis. This exclusion did not alter the result of the previous analysis, which indicates that the combined results were robust and reliable. Differences in the surgical process may be the major source of heterogeneity in Likun Xia's study (Table 2). Meanwhile, heterogeneity may have arisen from the limited number of studies and other external factors.

In terms of predictability, both groups achieved excellent postoperative mean refractive SE in the 12 included studies. We found no significant differences between the SMILE group and FS-LASIK group with regard to postoperative refractive SE. One included study [20] reported the proportion of eyes with postoperative refractions within  $\pm 0.50$  D of the targets (90.1% in the SMILE group and 76.6% in the FS-LASIK group) at the 6-month follow-up. Additionally, Ganesh demonstrated that the predictability of the SMILE group exceeded that of the FS-LA-SIK group because the creation of a flap in FS-LASIK exposes the stroma to hydration changes, leading to inaccurate removal of stromal tissue [24,29]. However, our analysis showed no differences in predictability between the two groups. The reason for this discrepancy may be the use of different laser platforms. There are trials reporting that VisuMax achieved fewer complications than IntraLase [30,31], the platform used for FS-LASIK in Ganesh and Gupta's study. All of the studies included in this meta-analysis used VisuMax.

Most contrastive studies with a SMILE group and an FS-LASIK group showed no significant difference in UCVA, CDVA or postoperative mean refractive SE [3,10,18,19,22,24,32], demonstrating that SMILE and FS-LASIK had comparable efficacy, safety, and predictability for treating myopia. However, when we focused on patients with high myopia, the results differed somewhat from our expectations. The SMILE group showed better postoperative CDVA than the FS-LASIK group, which suggests that SMILE may have a safety advantage over FS-LASIK when used to correct high myopia. The superior CDVA results of SMILE were also reflected in other articles for high myopia [6,7] and were statistically significant, but there was no difference for low or middle myopia [10,19,24,32]. The reason for this difference may be multifaceted. Andri K. Riau's study [32] suggested that, in vivo, the excimer laser used in LASIK released more cytokines and chemokines than are released in SMILE, recruiting more inflammatory cells to the surgical site. In contrast, SMILE, with a small incision size and femtosecond laser treatment, may result in a reduced wound healing response and corneal inflammation, both of which are important influences on visual acuity. These disparities were significant, especially at higher refractive corrections. In addition, it is worth noting that, during the procedure of FS-LASIK, the time required for stroma ablation is longer at higher degrees of myopia, which means that the corneal stroma bed must be exposed to the air and the laser for a longer time. This greatly reduced the compliance of patients during the operation, which may also account for the increased variability in the safety of LASIK for high myopia. However, this problem did not occur in SMILE because the open corneal flap was replaced by a short incision through which the lenticle was extracted. The duration of the SMILE procedure did not substantially change according to the severity of myopia, which also contributed to the safety advantage of SMILE over FS-LASIK for correcting high myopia.

The literature [33] has noted that, in the early stage after refractive surgery, patients are likely to experience glare, halos, or a decline in night vision as well as a variety of other changes in visual quality. There is some correlation between these changes and the increase in ocular aberration. The secondary outcomes suggested that, in both the SMILE group and the FS-LA-SIK group, the severity of postoperative aberrations significantly increased with long-term observation. Moreover, FS-LASIK introduced a larger tHOA, spherical aberration and coma than SMILE, which is consistent with the results of some of the studies in this meta-analysis [17,18,20,21].

Most importantly, postoperative tHOA increased more in the FS-LASIK group than in the SMILE group as of long-term follow-up. Possible reasons for the results are as follows. First, the two procedures remove corneal tissue in different manners. The increase in aberration after corneal refractive surgery is mainly induced by the corneal flap and stromal bed [5,13]. Because the deflection or displacement of the corneal flap can lead to a sharp increase in aberration, the effect of the corneal flap on tHOA is more obvious in FS-LASIK than in SMILE [11,34]. Especially in high myopia, some patients have relatively thin corneal flaps designed for safety reasons, placing them at an increased risk for corneal flap deflection or displacement. In contrast, there is no corneal flap in the SMILE process, which eliminates the risk of aberration caused by corneal flap positioning. Second, in SMILE, the small size of the incision and the extraction of the lenticule without a lifted flap reduce the disruption of the peripheral nerve and collagen fibers and preserve the structural integrity of the cornea more than FS-LASIK, which could be an important determining factor for higher-order aberration.

Spherical aberration of the cornea is one of the most important factors limiting the optical quality of the retinal image and the spatial resolution capabilities of the visual system. The occurrence of spherical aberration was influenced by biomechanical factors. SMILE maintains a more hermetic environment during the process of ablation, and the spherical features of the entire cornea are better preserved, which may explain why it introduces less spherical aberration than FS-LASIK in high myopia. In addition, during the process of corneal remodeling, a corneal flap increases the risk of a nonspherical change in the cornea, which will also contributes to the increase in spherical aberration [12].

Many scholars [13,21,34] have indicated that the changes in coma after SMILE and FS-LA-SIK have distinct characteristics. For instance, the small incision and separation of the lenticule in SMILE make the process of the wound different from that of FS-LASIK, and there is a considerable change in the coma along the direction of the incision (vertical) with only a small effect in the horizontal direction [13]. Other scholars have posited that the increase in vertical coma after SMILE is related to the imbalanced optical changes along the axis [21]. A certain amount of vertical coma may be beneficial to visual quality in high myopia; however, this view needs to be further discussed. In FS-LASIK, the location of the corneal flap hinge may determine the direction of the introduced coma. If the corneal flap is hinged on the nasal side, the coma along the axis of the flap increases significantly [34], whereas if the flap opens vertically, the coma in the vertical direction increases significantly [13]. Many published articles [35,36] have reported that, in moderate and low myopia, no significant difference was found between the SMILE group and the FS-LASIK group. In studies of high myopia [18,20,21], FS-LASIK always caused a more severe coma than SMILE, which is also consistent with our pooled results on coma. During the ablation process in FS-LASIK, high myopia can increase the amount of time that the corneal flap must remain open; thus, the recovery process will introduce a greater difference along the direction of the corneal flap. In SMILE, however, ablation takes the same amount of time regardless of the degree of myopia, which may explain why FS-LASIK introduces more coma than SMILE in high myopia.

The results of this meta-analysis should be interpreted in the context of several important limitations. First, the number of included clinical trials was relatively small, and only one randomized trial was included, which increased the risk of various types of bias. Second, the processed screening results showed that most of the included studies were performed in Asia, which may have caused publication bias. In addition, the extracted aberration data included various measurements from different wave-front analyzers, which increased the methodological bias.

In conclusion, SMILE and FS-LASIK had comparable safety and efficacy when used for correcting high myopia. However, this analysis indicated that the SMILE procedure may have advantages in some respects, especially for high myopia. SMILE introduced less tHOA, spherical aberration and coma than FS-LASIK. Ultimately, further randomized, double-blinded, prospective studies in high myopia over longer follow-up periods will be necessary to provide better evidence for this conclusion. Additionally, such studies would provide useful guidance in choosing between types of refractive surgery for patients with high myopia.

#### Supporting information

**S1 Table. Surgical procedures of the 10 included studies.** (DOCX)

**S2** Table. Summary of findings. (DOCX)

S1 Checklist. PRISMA NMA checklist of items to include when reporting a systematic review involving a network meta-analysis. (PDF)

#### **Author Contributions**

Conceptualization: Yanyan Fu, Xiaoying Wu, Dan Wen.

Data curation: Yanyan Fu, Aiqun Xiang, Ying Lu, Qiuman Fu.

Formal analysis: Yanyan Fu.

Funding acquisition: Yanyan Fu.

Investigation: Yanyan Fu, Yewei Yin, Aiqun Xiang, Tu Hu, Dan Wen.

Methodology: Yanyan Fu, Tu Hu.

Project administration: Yanyan Fu, Yewei Yin, Dan Wen.

Resources: Yanyan Fu, Ying Lu, Tu Hu.

Software: Yanyan Fu, Aiqun Xiang, Ying Lu, Qiuman Fu, Tu Hu.

Supervision: Yewei Yin, Xiaoying Wu, Yuanjun Li, Aiqun Xiang, Ying Lu, Dan Wen.

Validation: Yanyan Fu, Yewei Yin.

Visualization: Yanyan Fu, Yewei Yin.

Writing - original draft: Yanyan Fu.

Writing – review & editing: Yanyan Fu, Yewei Yin, Xiaoying Wu, Yuanjun Li, Tu Hu, Kaixuan Du, Dan Wen.

#### References

- Chen Y, Yin Y, Zhao Y, Wu X, Young K, Song W, et al. Differentiation of human embryonic stem cells derived mesenchymal stem cells into corneal epithelial cells after being seeded on decellularized SMILE-derived lenticules. Int J Ophthalmol 2019; 12(5):717–724. https://doi.org/10.18240/ijo.2019.05. 04 PMID: 31131228
- Wang B, Zhang Z, Rajeev K, Chu R, Dai J, Qu X, et al. Comparison of the change in posterior corneal elevation and corneal biomechanical parameters after small incision lenticule extraction and femtosecond laser-assisted LASIK for high myopia correction. Cont Lens Anterior Eye, 2016. 39(3): p. 191–6. https://doi.org/10.1016/j.clae.2016.01.007 PMID: 26852167
- 3. Wang B, Rajeev K, Chu R, Dai J, Qu X, Zhou H. Dry Eye Disease following Refractive Surgery: A 12-Month Follow-Up of SMILE versus FS-LASIK in High Myopia. J Ophthalmol, 2015. 20[1]15: p. 132417. https://doi.org/10.1155/2015/132417 PMID: 26649190
- Dupps W, Seven I. A Large-Scale Computational Analysis of Corneal Structural Response and Ectasia Risk in Myopic Laser Refractive Surgery. Trans Am Ophthalmol Soc. 2016 Aug; 114:T1. PMID: 27630372
- Qin B, Li M, Chen X, Walter S, Zhou X. Early visual outcomes and optical quality after femtosecond laser small-incision lenticule extraction for myopia and myopic astigmatism correction of over -10 dioptres. Acta Ophthalmol, 2018. 96(3): p. e341–e346. https://doi.org/10.1111/aos.13609 PMID: 29251814
- Qian Y, Chen X, Naidu RK, Zhou X. Comparison of efficacy and visual outcomes after SMILE and FS-LASIK for the correction of high myopia with the sum of myopia and astigmatism from -10.00 to -14.00 dioptres. Acta Ophthalmol. 2020; 98(2):e161–e72. Epub 2020/01/09. https://doi.org/10.1111/aos. 14078 PMID: 31912660.
- Han T, Shang J, Zhou X, Xu Y, Ang M, Zhou X. Refractive outcomes comparing small-incision lenticule extraction and femtosecond laser–assisted laser in situ keratomileusis for high myopia. Journal of Cataract and Refractive Surgery. 2020; 46(3):419–27. https://doi.org/10.1097/j.jcrs.000000000000075 PMID: 32142040
- Vryghem JC, Devogelaere T, Stodulka P. Efficacy, safety, and flap dimensions of a new femtosecond laser for laser in situ keratomileusis. J Cataract Refract Surg 2010; 36(3):442–448. https://doi.org/10. 1016/j.jcrs.2009.09.030 PMID: 20202543
- Sekundo W, Kunert KS, Blum M. Small incision corneal refractive surgery using the small incision lenticule extraction (SMILE) procedure for the correction of myopia and myopic astigmatism: results of a 6 month prospective study. Br J Ophthalmol. 2011; 95:335–339. https://doi.org/10.1136/bjo.2009.174284 PMID: 20601657
- Yan H, Gong L, Huang W, Peng Y. Clinical outcomes of small incision lenticule extraction versus femtosecond laser-assisted LASIK for myopia: a Meta-analysis. Int J Ophthalmol 2017; 10(9):1436–1445. https://doi.org/10.18240/ijo.2017.09.17 PMID: 28944205
- Yu M, Chen M, Wang B, Zou L, Zhu X, Dai J. Comparison of the visual results after SMILE and femtosecond laser-assisted LASIK for myopia. J Refract Surg. 2014; 30:248–254. https://doi.org/10.3928/ 1081597X-20140320-03 PMID: 24702576

- Agca A, Ozgurhan E, Demirok A, Bozkurt E, Celik U, Ozkaya A, et al. Comparison of corneal hysteresis and corneal resistance factor after small incision lenticule extraction and femtosecond laser-assisted LASIK: a prospective fellow eye study. Cont Lens Anterior Eye 2014; 37(2):77–80. <u>https://doi.org/10.1016/j.clae.2013.05.003</u> PMID: 23830802
- Wu D, Wang Y, Zhang L, Wei S, Tang X. Corneal biomechanical effects: smallincision lenticule extraction versus femtosecond laser-assisted laser in situ keratomileusis, J. Cataract Refract. Surg. 40 (2014) 954–962. https://doi.org/10.1016/j.jcrs.2013.07.056 PMID: 24751146
- Gyldenkerne A, Ivarsen A, Hjortdal JO. Comparison of corneal shape changes and aberrations induced By FS-LASIK and SMILE for myopia. J Refract Surg. 2015; 31(4):223–9. Epub 2015/03/10. <u>https://doi.org/10.3928/1081597X-20150303-01</u> PMID: 25751842.[2]
- Stroup DF, Berlin JA, Morton SC. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA. 2000; 283:2008–12. https://doi.org/10.1001/jama.283.15.2008 PMID: 10789670
- Moher D, Liberati A, Tetzlaff J, Group DGAP. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PloS Med. 2009; e100097. <u>https://doi.org/10.1097/MD.</u> 000000000017117 PMID: 31517849
- Xia L, Ma J, Liu H, Shi C, Huang Q. Three-year results of small incision lenticule extraction and wavefront guided femtosecond laser-assisted laser in situ keratomileusis for correction of high myopia and myopic astigmatism. Int J Ophthalmol. 2018; 11(3): 470–477. <u>https://doi.org/10.18240/ijo.2018.03.18</u> PMID: 29600182
- Han T, Xu Y, Han X, Zeng L, Shang J, Chen X, et al. "Three-year outcomes of small incision lenticule extraction (SMILE) and femtosecond laser-assisted laser in situ keratomileusis (FS-LASIK) for myopia and myopic astigmatism". Br J Ophthalmol. 2019; 103(4): 565–568. <u>https://doi.org/10.1136/ bjophthalmol-2018-312140 PMID: 30061116</u>
- Jing C. Clinical effect of SMILE and FS-LASIK and the effect on the stability of cornea and tear film. Department of Ophthalmology. Department of Ophthalmology, 2018, Vol.18(10):1866–1869.
- 20. Chen G, Zhao X. Clinical study on small incision lenticule extraction surgery for super high myopia. Guoji Yanke Zazhi (Int Eye Sci) 2017; 17(6):1130–1132
- Li X, Wang Y, Dou R. Aberration compensation between anterior and posterior corneal surfaces after Small incision lenticule extraction and Femtosecond laser-assisted laser in-situ keratomileusis. Ophthalmic Physiol Opt, 2015. 35(5): p. 540–51. https://doi.org/10.1111/opo.12226 PMID: 26087672
- Zhou Y, Chen J, Lin W. Analysis on postoperative variation of corneal posterior surface heights after femtosecond LASIK and small incision lenticule extraction of high myopia. Guoji Yanke Zazhi (Int Eye Sci) 2016; 16 (10): 1978–1980
- Zhou X, Shang J, Qin B, Zhao Y, Zhou X. Two-year observation of posterior corneal elevations after small incision lenticule extraction (SMILE) for myopia higher than -10 dioptres. Br J Ophthalmol, 2019. https://doi.org/10.1136/bjophthalmol-2018-313498 PMID: 31036587
- Pedersen IB, Bak-Nielsen S, Hjortdal A, Vestergaard H. Corneal biomechanical properties after LASIK, ReLEx flex, and ReLEx smile by Scheimpflug-based dynamic tonometry. Graefes Arch Clin Exp Ophthalmol, 2014. 252(8): p. 1329–35. https://doi.org/10.1007/s00417-014-2667-6 PMID: 24862302
- Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315:629–34. https://doi.org/10.1136/bmj.315.7109.629 PMID: 9310563
- Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50:1088–101. PMID: 7786990
- Shen Z, Shi K, Yu Y, Yu X, Lin Y, Yao K. Small Incision Lenticule Extraction (SMILE) versus Femtosecond Laser-Assisted In Situ Keratomileusis (FS-LASIK) for Myopia: A Systematic Review and Meta-Analysis. PLoS One. 2016; 11(7):e0158176. Epub 2016/07/02. <u>https://doi.org/10.1371/journal.pone.</u> 0158176 PMID: 27367803.
- Yan H, Gong LY, Huang W, Peng YL. Clinical outcomes of small incision lenticule extraction versus femtosecond laser-assisted LASIK for myopia: a Meta-analysis. Int J Ophthalmol. 2017; 10(9):1436– 45. Epub 2017/09/26. https://doi.org/10.18240/ijo.2017.09.17 PMID: 28944205.
- Ganesh S, Gupta R. Comparison of visual and refractive outcomes following femtosecond laser-assisted LASIK with SMILE in patients with myopia or myopic astigmatism. J Refract Surg. 2014; 30:590–6. https://doi.org/10.3928/1081597x-20140814-02 PMID: 25250415
- Hall RC, Rosman M, Chan C, Tan DT, Mehta JS. Patient and surgeon experience during laser in situ keratomileusis using 2 femtosecond laser systems. J Cataract Refract Surg. 2014; 40:423–9. <a href="https://doi.org/10.1016/j.jcrs.2013.08.056">https://doi.org/10.1016/j.jcrs.2013.08.056</a> PMID: 24461333
- Petznick A, Chew A, Hall RC, Chan CM, Rosman M, Tan D, et al. Comparison of corneal sensitivity, tear function and corneal staining following laser in situ keratomileusis with two femtosecond laser platforms. Clinical ophthalmology (Auckland, NZ). 2013; 7:591–8.

- Yu M, Chen M, Wang B, Zou L, Zhu X, Dai J. Comparison of Visual Quality After SMILE and LASEK for Mild to Moderate Myopia, J Refract Surg, 2015. 31(12): p. 798–800. <u>https://doi.org/10.3928/1081597X-20151111-02</u> PMID: 26653723
- 33. Wu Y, Huang Z. Comparison of early visual quality in patients with moderate myopia using different optical zones in small incision lenticule extraction (SMILE). BMC Ophthalmol. 2021; 21(1):46. Published 2021 Jan 19. https://doi.org/10.1186/s12886-020-01798-y PMID: 33468076
- Pallikaris I, Kymionis G, Panagopoulou S, Siganos C, Theodorakis M, Pallikaris A. Induced optical aberrations following formation of a laser in situ keratomileusis flap. J Cataract Refract Surg 2002; 28 (10):1737–1742. https://doi.org/10.1016/s0886-3350(02)01507-9 PMID: 12388021
- Damgaard I, Ang M, Farook M, Htoon H, Mehta J. Intraoperative Patient Experience and Postoperative Visual Quality After SMILE and LASIK in a Randomized, Paired-Eye, Controlled Study. J Refract Surg, 2018. 34(2): p. 92–99. https://doi.org/10.3928/1081597X-20171218-01 PMID: 29425387
- Yu M, Chen M, Wang B, Zou L, Zhu X, Dai J. Comparison of the visual results after SMILE and femtosecond laser-assisted LASIK for myopia. J Refract Surg. 2014; 30:248–254. <u>https://doi.org/10.3928/ 1081597X-20140320-03 PMID: 24702576</u>